

Andrei Gudkov

Serial or Patent No:

Herewith

For: p53 INHIBITORS AND THERAPEUTIC USE OF THE SAME

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(d)) -- NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: The Board of Trustees of the University of Illinois
ADDRESS OF ORGANIZATION: 352 Henry Administration Building
506 South Wright Street
Urbana, Illinois 61801

TYPE OF ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- ☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
- ☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501 (a) and 501 (c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(NAME OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled p53 INHIBITORS AND THERAPEUTIC USE OF THE SAME, by inventor(s) Andrei V. Gudkov, Pavel G. Komarov, and Elena A. Komarova described in

- ☒ The specification filed herewith.
☐ Application Serial No. , filed .
☐ Patent No. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above-identified invention. If the rights

held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below, and must file separate verified statements averring to their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME: Quark Biotech, Inc.
ADDRESS: 1059 Serpentine Lane
Pleasanton, California 94566

☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Craig S. Bazzani

TITLE IN ORGANIZATION: Comptroller and Vice-President
for Business and Finance

ADDRESS OF PERSON SIGNING: 349 Henry Administration Building
506 South Wright Street

SIGNATURE: Craig S. Bazzani Date: 1-13-2000

PATENT

Attorney's Docket No. 27611/35214A

Applicant or Patentee: Andrei Gudkov et al.

Serial or Patent No: _____

Filed or Issued: Herewith

For: p53 INHIBITORS AND THERAPEUTIC USE OF THE SAME

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(c)) -- SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ The owner of the small business concern identified below:
- ☒ An official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Quark Biotech, Inc.

ADDRESS OF BUSINESS 1059 Serpentine Lane
Pleasanton, California 94566

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to, and remain with, the small business concern identified above with regard to the invention, entitled p53 inhibitors and Therapeutic Use of the Same, by inventor(s) Andrei V. Gudkov et al., described in

- ☒ The specification filed herewith.
- ☐ Application Serial No. _____, filed _____.
- ☐ Patent No. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no

Received Time

Jan. 24. 8:13AM

Print Time

Jan. 24. 8:24AM

0000017-06-001

rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c), if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

***NOTE:** *Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).*

NAME: The Board of Trustees of the University of Illinois
ADDRESS: 352 Henry Administration Building, 506 South Wright Street,
Urbana, Illinois 61801

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☒ NONPROFIT ORGANIZATION

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:
TITLE OF PERSON OTHER THAN OWNER:
ADDRESS OF PERSON SIGNING:

Daniel Zurr
President and CEO
1059 Serpentine Lane
Pleasanton, California 94566

SIGNATURE: _____

Date 24 January, 2008

- 2 -

Received Time

Jan. 24. 8:13AM

Print Time

Jan. 24. 8:23AM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):)
ANDREI V. GUDKOV ET AL.) Title: p53 INHIBITORS AND
Serial No. 09/493,527) THERAPEUTIC USE OF THE SAME
Filed: January 28, 2000)

TRANSMITTAL OF EXECUTED DECLARATION

***Assistant Commissioner for Patents
Washington, D.C. 20231***


Attention: BOX MISSING PART

Sir:

Submitted herewith is an executed Declaration for filing in the above-identified application, in response to the Notice to File Missing Parts issued by the Patent and Trademark Office on March 27, 2000.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper and the documents referred to as enclosed therewith are being deposited with the United States Postal Service as first class mail, postage prepaid, on April 6, 2000, in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.


James J. Napoli


Also enclosed is a copy of the Notice together with our check in the amount of \$130.00 in payment of the fee.

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 13-2855. A copy of this request is enclosed.

Please refund any overpayment to Marshall, O'Toole, Gerstein, Murray & Borun at the address below.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By: 
James J. Napoli
Reg. No. 32,361

April 6, 2000

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention of **53 INHIBITORS AND THERAPEUTIC USE OF THE SAME** the specification of which (check one): ☒ is attached hereto and ☐ was filed on _____ as Application Serial No. _____ and was amended on _____ (if applicable); ☐ was filed as PCT International Application No. _____ on _____ and was published under Article 19 on _____ (if applicable). I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as set forth in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America listed below and not identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date earlier than the application(s) of which priority is claimed:

Serial Number	(Country)	(Day/Month/Year Filed)	Priority Claimed
			Yes No
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			
61			
62			
63			
64			
65			
66			
67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			

Serial Number	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
---------------	-----------	------------------------	------------------------------	-----------------------------

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

81
 (on Serial Number) 29/01/99
 (Day/Month/Year Filed)

on Serial Number) (Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) originating from the United States of America listed below and, insofar as the subject matter of each of the claims of this application is supported in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred on or after the filing date of the prior application(s) and the national or PCT international filing date of this application:

n Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
------------------	------------------------	---

Serial Number	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
1	10/10/2010	Patented
2	10/10/2010	Patented
3	10/10/2010	Patented
4	10/10/2010	Patented
5	10/10/2010	Patented
6	10/10/2010	Patented
7	10/10/2010	Patented
8	10/10/2010	Patented
9	10/10/2010	Patented
10	10/10/2010	Patented
11	10/10/2010	Patented
12	10/10/2010	Patented
13	10/10/2010	Patented
14	10/10/2010	Patented
15	10/10/2010	Patented
16	10/10/2010	Patented
17	10/10/2010	Patented
18	10/10/2010	Patented
19	10/10/2010	Patented
20	10/10/2010	Patented
21	10/10/2010	Patented
22	10/10/2010	Patented
23	10/10/2010	Patented
24	10/10/2010	Patented
25	10/10/2010	Patented
26	10/10/2010	Patented
27	10/10/2010	Patented
28	10/10/2010	Patented
29	10/10/2010	Patented
30	10/10/2010	Patented
31	10/10/2010	Patented
32	10/10/2010	Patented
33	10/10/2010	Patented
34	10/10/2010	Patented
35	10/10/2010	Patented
36	10/10/2010	Patented
37	10/10/2010	Patented
38	10/10/2010	Patented
39	10/10/2010	Patented
40	10/10/2010	Patented
41	10/10/2010	Patented
42	10/10/2010	Patented
43	10/10/2010	Patented
44	10/10/2010	Patented
45	10/10/2010	Patented
46	10/10/2010	Patented
47	10/10/2010	Patented
48	10/10/2010	Patented
49	10/10/2010	Patented
50	10/10/2010	Patented
51	10/10/2010	Patented
52	10/10/2010	Patented
53	10/10/2010	Patented
54	10/10/2010	Patented
55	10/10/2010	Patented
56	10/10/2010	Patented
57	10/10/2010	Patented
58	10/10/2010	Patented
59	10/10/2010	Patented
60	10/10/2010	Patented
61	10/10/2010	Patented
62	10/10/2010	Patented
63	10/10/2010	Patented
64	10/10/2010	Patented
65	10/10/2010	Patented
66	10/10/2010	Patented
67	10/10/2010	Patented
68	10/10/2010	Patented
69	10/10/2010	Patented
70	10/10/2010	Patented
71	10/10/2010	Patented
72	10/10/2010	Patented
73	10/10/2010	Patented
74	10/10/2010	Patented
75	10/10/2010	Patented
76	10/10/2010	Patented
77	10/10/2010	Patented
78	10/10/2010	Patented
79	10/10/2010	Patented
80	10/10/2010	Patented
81	10/10/2010	Patented
82	10/10/2010	Patented
83	10/10/2010	Patented
84	10/10/2010	Patented
85	10/10/2010	Patented
86	10/10/2010	Patented
87	10/10/2010	Patented
88	10/10/2010	Patented
89	10/10/2010	Patented
90	10/10/2010	Patented
91	10/10/2010	Patented
92	10/10/2010	Patented
93	10/10/2010	Patented
94	10/10/2010	Patented
95	10/10/2010	Patented
96	10/10/2010	Patented
97	10/10/2010	Patented
98	10/10/2010	Patented
99	10/10/2010	Patented
100	10/10/2010	Patented

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information furnished to me are believed to be true; and further that these statements were made with the knowledge that willful false statements and omissions made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may constitute perjury and may constitute fraud in the procurement of the patent and may constitute fraud on the Patent Office and may vitiate the validity of the application or any patent issued thereon.

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.